Latest Quarterly Activities News

Litchfield Minerals has confirmed a large copper-zinc system and uncovered a new gold-bismuth mineralisation style at its Northern Territory Oonagalabi Project, supported by government grants and ongoing exploration.

Challenger Gold has completed a Pre-Feasibility Study for toll milling at its Hualilan Gold Project in Argentina, revealing strong economics with low upfront capital and rapid payback. The company also secured A$37.5 million in equity funding to advance development and strengthened legal protections for its Ecuador projects.

Althea Group Holdings reported significant cash outflows in Q2 2025 due to one-off costs but anticipates operational improvements and revenue growth from its North American business units.

Babylon Pump & Power capped FY25 with its strongest rental segment performance and is poised to expand significantly following imminent acquisitions of Matrix Hydro Services and Blue Hire.

Sultan Resources advances exploration in NSW’s Lachlan Fold Belt with promising gold-copper targets while managing a modest capital raise and reviewing WA assets.

Skin Elements Limited advances its proprietary SE Formula biotechnology with ECO-Nurture poised for commercial rollout in 2026, alongside progress in disinfectant and sunscreen product lines.

Hexima Limited reported a stable cash balance of AUD 1.54 million for Q2 2025, with only minor net cash used in operating activities. The company remains focused on strategic opportunities to enhance shareholder value.

North Stawell Minerals confirms fresh gold mineralisation at Darlington West, backed by a $3.6 million equity raise to fund expanded drilling and exploration across its Victorian projects.

Marquee Resources has progressed its Mt Clement antimony-gold project with Phase 1 drilling completed and assay results pending, alongside a $596,000 capital raise and a key executive appointment.

Enterprise Metals Ltd reported significant progress across multiple Western Australian projects in its June 2025 quarterly update, supported by a government drilling grant and a $780,000 share placement.

Tissue Repair Limited reports steady progress in its Phase 3 clinical trials for TR987® despite patient recruitment hurdles, while TR Pro+® sales surge and new distribution deals pave the way for international growth.

Fintech Chain Limited reported a mixed quarter with strong customer receipts and new IoT SaaS product launch, while finalising its ASX delisting. The company’s cash position tightened amid loan repayments and rising operating costs.